# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biora Therapeutics shares are trading lower by 45% during Tuesday's session. The company announced that it will be delisted...
HC Wainwright & Co. analyst Joseph Pantginis maintains Biora Therapeutics (NASDAQ:BIOR) with a Buy, adjusts target to $23 f...
Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(5.04) per share which missed the analyst consensus estimate of ...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that it has enter...